{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Stable disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Clinical benefit rate (CBR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"CBR determined by investigator assessment for each tumor assessment \\& defined as responses of Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) ≥ 16 wks. Confirmed CR/PR or SD prior to 16 wks,but discontinued prior to 16 wks for reasons other than progressive disease,will have their clinical benefit defined non-evaluable; confirmed CR/PR or SD prior to 16 wks,but progressed prior to 16 wks,will be considered not achieving clinical benefit;if CR/PR/SD occurred prior to 16 wks,but progressed at or after 16 wks without evidence of CR/PR/SD at or after 16 wks,will also be considered not achieving clinical benefit. CBR will be analyzed by comparing achieved CBR with a historical control rate of each tumor type,\\& if there is at least 90% probability that the response rate in a tumor type exceeds the historical rate,then the tumor type will be considered a success. CBR: CR+PR+SD the assessment criteria was RECIST 1.1","groups":[{"description":"Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.","id":"OG000","title":"TKI258"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) included all patients who received at least one dose of study drug.\n\nFAS was used for the analysis of efficacy endpoints.","reportingStatus":"POSTED","timeFrame":"Week 16","title":"Clinical Benefit Rate (CBR)","type":"PRIMARY","unitOfMeasure":"number of participants"}